Diabetes Awareness, Treatment, and Control among Mexico City Residents
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Barquera, S.; Pedroza-Tobias, A.; Medina, C. Cardiovascular diseases in mega-countries. Curr. Opin. Lipidol. 2016, 27, 329–344. [Google Scholar] [CrossRef] [Green Version]
- Basto-Abreu, A.; Barrientos-Gutierrez, T.; Rojas-Martínez, R.; Aguilar-Salinas, C.A.; López-Olmedo, N.; De La Cruz-Góngora, V.; Dommarco, J.A.R.; Shamah-Levy, T.; Romero-Martínez, M.; Barquera, S.; et al. Prevalencia de diabetes y descontrol glucémico en México: Resultados de la Ensanut 2016. Salud Pública de México 2019, 62, 50–59. [Google Scholar] [CrossRef]
- Rivera, M.J.A.; Barquera, S.; González-Cossío, M.T.; Olaiz, M.G.; Sepúlveda, M.J. Nutrition Transition in Mexico and in Other Latin American Countries. Nutr. Rev. 2004, 62, S149–S157. [Google Scholar] [CrossRef]
- Dommarco, J.A.R.; Barquera, S.; Campirano, F.; Campos-Nonato, I.; Safdie, M.; Tovar, V. Epidemiological and nutritional transition in Mexico: Rapid increase of non-communicable chronic diseases and obesity. Public Health Nutr. 2002, 5, 113–122. [Google Scholar] [CrossRef]
- Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 2018, 14, 88–98. [Google Scholar] [CrossRef] [PubMed]
- Medina, C.; Coxson, P.; Penko, J.; Janssen, I.; Bautista-Arredondo, S.; Barquera, S.; Bibbins-Domingo, K. Cardiovascular and diabetes burden attributable to physical inactivity in Mexico. Cardiovasc. Diabetol. 2020, 19, 1–9. [Google Scholar] [CrossRef]
- Medina, C.; Tolentino-Mayo, L.; Lopez-Ridaura, R.; Barquera, S. Evidence of increasing sedentarism in Mexico City during the last decade: Sitting time prevalence, trends, and associations with obesity and diabetes. PLoS ONE 2017, 12, e0188518. [Google Scholar] [CrossRef] [Green Version]
- Stern, D.; Piernas, C.; Barquera, S.; Rivera, J.A.; Popkin, B.M. Caloric Beverages Were Major Sources of Energy among Children and Adults in Mexico, 1999–2012. J. Nutr. 2014, 144, 949–956. [Google Scholar] [CrossRef] [Green Version]
- García-Chávez, C.G.; Rodríguez-Ramírez, S.; Dommarco, J.A.R.; Monterrubio-Flores, E.; Tucker, K.L. Sociodemographic factors are associated with dietary patterns in Mexican schoolchildren. Public Health Nutr. 2017, 21, 702–710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Denova-Gutiérrez, E.; Muñoz-Aguirre, P.; Shivappa, N.; Hebert, J.R.; Tolentino-Mayo, L.; Batis, C.; Barquera, S. Dietary Inflammatory Index and Type 2 Diabetes Mellitus in Adults: The Diabetes Mellitus Survey of Mexico City. Nutrients 2018, 10, 385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marrón-Ponce, J.A.; Tolentino-Mayo, L.; Hernández, -F.M.; Batis, C. Trends in Ultra-Processed Food Purchases from 1984 to 2016 in Mexican Households. Nutrients 2018, 11, 45. [Google Scholar] [CrossRef] [Green Version]
- Gómez-Dantés, H.; Fullman, N.; Lamadrid-Figueroa, H.; Cahuana-Hurtado, L.; Darney, B.; Avila-Burgos, L.; Correa-Rotter, R.; Rivera, J.A.; Barquera, S.; González-Pier, E.; et al. Dissonant health transition in the states of Mexico, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2016, 388, 2386–2402. [Google Scholar] [CrossRef]
- Barquera, S.; Campos-Nonato, I.; Aguilar-Salinas, C.A.; López-Ridaura, R.; Arredondo, A.; Dommarco, J.A.R. Diabetes in Mexico: Cost and management of diabetes and its complications and challenges for health policy. Glob. Health 2013, 9, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barcelo, A.; Arredondo, A.; Gordillo–Tobar, A.; Segovia, J.; Qiang, A. The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers. J. Glob. Health 2017, 7, 020410. [Google Scholar] [CrossRef] [PubMed]
- Panton, U.H.; Bagger, M.; Barquera, S. Projected diabetes prevalence and related costs in three North American urban centres (2015–2040). Public Health 2018, 157, 43–49. [Google Scholar] [CrossRef] [PubMed]
- Chung, W.K.; Erion, K.; Florez, J.C.; Hattersley, A.T.; Hivert, M.-F.; Lee, C.G.; McCarthy, M.I.; Nolan, J.J.; Norris, J.M.; Pearson, E.R.; et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020, 43, 1617–1635. [Google Scholar] [CrossRef] [PubMed]
- Roglic, G. WHO Global report on diabetes: A summary. Int. J. Noncommun. Dis. 2016, 1, 3. [Google Scholar] [CrossRef]
- Flores-Hernández, S.; Saturno-Hernández, P.J.; Reyes-Morales, H.; Barrientos-Gutiérrez, T.; Villalpando, S.; Hernández-Ávila, M. Quality of Diabetes Care: The Challenges of an Increasing Epidemic in Mexico. Results from Two National Health Surveys (2006 and 2012). PLoS ONE 2015, 10, e0133958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Napier, A.D.; Nolan, J.J.; Bagger, M.; Hesseldal, L.; Volkmann, A.-M. Study protocol for the Cities Changing Diabetes programme: A global mixed-methods approach. BMJ Open 2017, 7, e015240. [Google Scholar] [CrossRef] [PubMed]
- Holm, A.L.; Andersen, G.S.; Jørgensen, M.E.; Diderichsen, F. Is the Rule of Halves framework relevant for diabetes care in Copenhagen today? A register-based cross-sectional study. BMJ Open 2018, 8, e023211. [Google Scholar] [CrossRef] [Green Version]
- Wilkerson, H.L.C.; Krall, L.P. Diabetes in a new England town. J. Am. Med. Assoc. 1947, 135, 209–216. [Google Scholar] [CrossRef]
- Weinehall, L.; Bengt, Ö.; Persson, M.; Stegmayr, B.; Boman, K.; Hallmans, G.; Lindholm, L. High remaining risk in poorly treated hypertension: The ‘rule of halves’ still exists. J. Hypertens. 2002, 20, 2081–2088. [Google Scholar] [CrossRef] [PubMed]
- Denova-Gutiérrez, E.; Vargas-Chanes, D.; Hernández, S.; Muñoz-Aguirre, P.; Napier, D.; Barquera, S. Linking socioeconomic inequalities and type 2 diabetes through obesity and lifestyle factors among Mexican adults: A structural equations modeling approach. Salud Pública México 2020, 62, 192–202. [Google Scholar] [CrossRef] [Green Version]
- Bijlsma-Rutte, A.; Rutters, F.; Elders, P.J.; Bot, S.D.; Nijpels, G. Socio-economic status and HbA1c in type 2 diabetes: A systematic review and meta-analysis. Diabetes/Metab. Res. Rev. 2018, 34, e3008. [Google Scholar] [CrossRef]
- Addo, J.; Agyemang, C.; Aikins, A.D.-G.; Beune, E.; Schulze, M.B.; Danquah, I.; Galbete, C.; Nicolaou, M.; Meeks, K.; Klipstein-Grobusch, K.; et al. Association between socioeconomic position and the prevalence of type 2 diabetes in Ghanaians in different geographic locations: The RODAM study. J. Epidemiol. Community Health 2017, 71, 633–639. [Google Scholar] [CrossRef] [Green Version]
- Agardh, E.E.; Allebeck, P.; Hallqvist, J.; Moradi, T.; Sidorchuk, A. Type 2 diabetes incidence and socio-economic position: A systematic review and meta-analysis. Int. J. Epidemiol. 2011, 40, 804–818. [Google Scholar] [CrossRef] [Green Version]
- Dagenais, G.R.; Gerstein, H.C.; Zhang, X.; McQueen, M.; Lear, S.; Lopez-Jaramillo, P.; Mohan, V.; Mony, P.; Gupta, R.; Kutty, V.R.; et al. Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. Diabetes Care 2016, 39, 780–787. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moradi, G.; Majdzadeh, R.; Mohammad, K.; Malekafzali, H.; Jafari, S.; Holakouie-Naieni, K. Is the status of diabetes socioeconomic inequality changing in Kurdistan province, west of Iran? A comparison of two surveys. Med. J. Islam. Repub. Iran 2016, 30, 375. [Google Scholar] [PubMed]
- De Silva, A.P.; De Silva, A.P.; Haniffa, R.; Liyanage, I.K.; Jayasinghe, S.; Katulanda, P.; Wijeratne, C.N.; Wijeratne, S.; Rajapaksa, L.C. Inequalities in the prevalence of diabetes mellitus and its risk factors in Sri Lanka: A lower middle income country. Int. J. Equity Heath 2018, 17, 45. [Google Scholar] [CrossRef]
- Biswas, T.; Islam, S.; Linton, N.; Rawal, L.B. Socio-Economic Inequality of Chronic Non-Communicable Diseases in Bangladesh. PLoS ONE 2016, 11, e0167140. [Google Scholar] [CrossRef] [Green Version]
- Chaturvedi, N.; Jarrett, J.; Shipley, M.J.; Fuller, J.H. Socioeconomic gradient in morbidity and mortality in people with diabetes: Cohort study findings from the Whitehall study and the WHO multinational study of vascular disease in diabetes. BMJ 1998, 316, 100–105. [Google Scholar] [CrossRef] [Green Version]
- O’Kane, M.; McMenamin, M.; Bunting, B.; Moore, A.; Coates, V. The relationship between socioeconomic deprivation and metabolic/cardiovascular risk factors in a cohort of patients with type 2 diabetes mellitus. Prim. Care Diabetes 2010, 4, 241–249. [Google Scholar] [CrossRef] [PubMed]
- Dray-Spira, R.; Gary-Webb, T.L.; Brancati, F.L. Educational Disparities in Mortality Among Adults with Diabetes in the U.S. Diabetes Care 2010, 33, 1200–1205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sánchez-Barriga, J.J. Mortality trends from diabetes mellitus in the seven socioeconomic regions of Mexico, 2000-2007. Revista Panam. de Salud Pública 2010, 28, 368–375. [Google Scholar] [CrossRef] [Green Version]
- Rojas-Martínez, R.; Basto-Abreu, A.; Aguilar-Salinas, C.A.; Zárate-Rojas, E.; Villalpando, S.; Barrientos-Gutiérrez, T. Prevalencia de diabetes por diagnóstico médico previo en México. Salud Pública México 2018, 60, 224–232. [Google Scholar] [CrossRef]
- González-Villalpando, C.; Dávila-Cervantes, C.A.; Zamora-Macorra, M.; Trejo-Valdivia, B.; González-Villalpando, M.E. Incidence of type 2 diabetes in Mexico: Results of the Mexico City Diabetes Study after 18 years of follow-up. Salud Pública México 2014, 56, 11–17. [Google Scholar] [CrossRef] [Green Version]
- Whittemore, R.; Vilar-Compte, M.; De La Cerda, S.; Marron, D.; Conover, R.; Delvy, R.; Lozano-Marrufo, A.; Perez-Escamilla, R. Challenges to diabetes self-management for adults with type 2 diabetes in low-resource settings in Mexico City: A qualitative descriptive study. Int. J. Equity Health 2019, 18, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Barquera, S.; Campos-Nonato, I.; Carrión-Rábago, C.; Villalpando, S.; López-Ridaura, R.; Rojas, R.; Aguilar-Salinas, C.A. Methodology for the analysis of type 2 diabetes, metabolic syndrome and cardiovascular disease risk indicators in the ENSANUT 2006. Salud Pública México 2010, 52, S4–S10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes. Diabetes Care 2017, 40 (Suppl. 1), S11–S24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiménez-Corona, A.; Aguilar-Salinas, C.A.; Rojas-Martínez, R.; Hernández-Ávila, M. Type 2 diabetes and frequency of prevention and control measures. Salud Pública México 2013, 55, S137–S143. [Google Scholar]
- Villalobos, A.; Rojas, R.; Aguilar-Salinas, C.A.; Romero-Martínez, M.; Mendoza-Alvarado, L.R.; Flores-Luna, M.D.L.; Escamilla, A.; Ávila-Burgos, L. Atención médica y acciones de autocuidado en personas que viven con diabetes, según nivel socioeconómico. Salud Pública México 2019, 61, 876–887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- American Diabetes Association. Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers. Clin. Diabetes 2019, 37, 11–34. [Google Scholar] [CrossRef] [Green Version]
- Martin, S.S.; Blaha, M.J.; Elshazly, M.B.; Toth, P.P.; Kwiterovich, P.O.; Blumenthal, R.S.; Jones, S.R. Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile. JAMA 2013, 310, 2061–2068. [Google Scholar] [CrossRef] [PubMed]
- Miller, M.; Stone, N.J.; Ballantyne, C.; Bittner, V.; Criqui, M.H.; Ginsberg, H.N.; Goldberg, A.C.; Howard, W.J.; Jacobson, M.S.; Kris-Etherton, P.M.; et al. Triglycerides and Cardiovascular Disease. Circulation 2011, 123, 2292–2333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Detection, E.E.P.O. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285, 2486–2497. [Google Scholar] [CrossRef]
- Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.J.L.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.J.T.; et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 Report. JAMA 2003, 289, 2560–2571. [Google Scholar] [CrossRef]
- Gutiérrez, J.P. Clasificación socio-económica de los hogares en la ENSANUT 2012. Salud Publica Mex 2013, 55, S342–S346. [Google Scholar] [CrossRef]
- Medina, C.; Barquera, S.; Janssen, I. Validity and reliability of the International Physical Activity Questionnaire among adults in Mexico. Revista Panam. de Salud Pública 2013, 34, 21–28. [Google Scholar]
- Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)-Short and Long Forms. November 2005. Available online: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnx0aGVpcGFxfGd4OjE0NDgxMDk3NDU1YWRlZTM. (accessed on 10 February 2021).
- Alberti, K.G.M.M.; Zimmet, P.; Shaw, J. The metabolic syndrome—A new worldwide definition. Lancet 2005, 366, 1059–1062. [Google Scholar] [CrossRef]
- World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Expert Consultation; Technical Report Series No. 894; WHO: Geneva, Switzerland, 2000. [Google Scholar]
- Kalra, S.; Saboo, B.; Sahay, R.; Khandelwal, D.; Talwar, V.; Unnikrishnan, A.G. The rule of two-thirds in diabetes epidemiology. Indian J. Endocrinol. Metab. 2017, 21, 242–244. [Google Scholar] [CrossRef]
- Hart, J.T. Rule of halves: Implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care. Br. J. Gen. Pr. 1992, 42, 116–119. [Google Scholar]
- Gakidou, E.; Mallinger, L.; Abbott-Klafter, J.; Guerrero, R.; Villalpando, S.; Ridaura, R.L.; Aekplakorn, W.; Naghavi, M.; Lim, S.; Lozano-Ascencio, R.; et al. Management of diabetes and associated cardiovascular risk factors in seven countries: A comparison of data from national health examination surveys. Bull. World Health Organ. 2010, 89, 172–183. [Google Scholar] [CrossRef] [PubMed]
- Arredondo, A.; Azar, A.; Recamán, A.L. Diabetes, a global public health challenge with a high epidemiological and economic burden on health systems in Latin America. Glob. Public Health 2017, 13, 780–787. [Google Scholar] [CrossRef] [PubMed]
- Villalpando, S.; De La Cruz-Góngora, V.; Rojas, R.; Shamah-Levy, T.; Avila, M.A.; Gaona, B.; Rebollar, R.; Hernández, L. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: A probabilistic survey. Salud Pública México 2010, 52, S19–S26. [Google Scholar] [CrossRef] [Green Version]
- Olaiz-Fernández, G.; Rivera-Dommarco, J.; Shamah-Levy, T.; Rojas, R.; Villalpando-Hernández, S.; Hernández-Avila, M.; Sepúlveda-Amor, J. Encuesta Nacional de Salud y Nutrición 2006; Instituto Nacional de Salud Pública: Cuernavaca, Mexico, 2006. [Google Scholar]
- Villalobos, A.; Aguilar-Salinas, C.A.; Romero-Martínez, M.; Rojas-Martínez, R. Population profiles associated with attendance at preventive services to screening tests. Ensanut 2018-19. Salud Pública México 2020, 62, 754–766. [Google Scholar] [CrossRef]
- Marín-Navarrete, R.; Villalobos-Gallegos, L.; Medina-Mora, M.E.; Magis-Rodriguez, C. Rapid testing and counseling for HIV/STIs in Mexican community-based residential care facilities for substance use disorders: A prospective study protocol. J. Subst. Use 2019, 24, 329–335. [Google Scholar] [CrossRef]
- Marín-Navarrete, R.; Magis-Rodríguez, C.; Villalobos-Gallegos, L.; Villafuerte-García, A.; Pérez-López, A.; Ruiz-Herrera, K.; Sánchez-Domínguez, R.; Ponce-Ramos, M.; Morales-Carcaño, A.; Bravo-García, E.; et al. Development of an evidence-based model of rapid testing, counseling and referral patients with HIV, HVC and other STDs in Mexican addiction treatment centers. Salud Ment. 2019, 42, 191–201. [Google Scholar] [CrossRef]
- Gómez-Velasco, D.V.; Paloma, A.-V.; Martagón, A.J.; Galán-Ramírez, G.A.; Aguilar-Salinas, C.A. Empowerment of patients with type 2 diabetes: Current perspectives. Diabetes Metab. Syndr. Obesity Targets Ther. 2019, 12, 1311–1321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mendoza-Herrera, K.; Quezada, A.D.; Pedroza-Tobías, A.; Hernández-Alcaraz, C.; Fromow-Guerra, J.; Barquera, S. A Diabetic Retinopathy Screening Tool for Low-Income Adults in Mexico. Prev. Chronic Dis. 2017, 14, E95. [Google Scholar] [CrossRef] [Green Version]
- Cuadros, J.; Bresnick, G. EyePACS: An Adaptable Telemedicine System for Diabetic Retinopathy Screening. J. Diabetes Sci. Technol. 2009, 3, 509–516. [Google Scholar] [CrossRef] [Green Version]
- Lim, L.L.; Lau, E.S.; Kong, A.P.; Davies, M.J.; Levitt, N.; Eliasson, B.; Aguilar-Salinas, C.A.; Ning, G.; Seino, Y.; So, W.-Y.; et al. Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. Diabetes Care 2018, 41, 1312–1320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hernández-Jiménez, S.; García-Ulloa, A.C.; Bello-Chavolla, O.Y.; Aguilar-Salinas, C.A.; Kershenobich-Stalnikowitz, D. Long-term effectiveness of a type 2 diabetes comprehensive care program. The CAIPaDi model. Diabetes Res. Clin. Pr. 2019, 151, 128–137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, S.A. The Effect of Social Desirability and Social Approval on Self-Reports of Physical Activity. Am. J. Epidemiol. 2005, 161, 389–398. [Google Scholar] [CrossRef] [PubMed]
Characteristic | n | N (Thousands) | % (95% CI) 1 |
---|---|---|---|
Gender | |||
Men | 489 | 2,552,120 | 46.9 (43.9, 49.9) |
Women | 818 | 2,888,195 | 53.1 (50.1, 56.1) |
Age group | |||
20–39 | 492 | 2,892,281 | 53.2 (49.6, 56.7) |
40–59 | 572 | 2,030,659 | 37.3 (33.5, 41.3) |
60+ | 243 | 517,374 | 9.5 (7.7, 11.6) |
Education | |||
Elementary or less | 370 | 1,035,269 | 19.0 (16.3, 22.1) |
Secondary | 384 | 1,512,950 | 27.8 (24.4, 31.5) |
High school or higher | 553 | 2,892,096 | 53.2 (48.8, 57.4) |
Parent diagnosed with diabetes | 565 | 2,170,385 | 42.0 (38.7, 45.4) |
Socioeconomic status | |||
Tertile 1 | 405 | 1,196,362 | 22.0 (18.5, 26.0) |
Tertile 2 | 488 | 1,978,067 | 36.4 (32.2, 40.7) |
Tertile 3 | 414 | 2,265,886 | 41.6 (36.4, 47.1) |
Primary health care provider | |||
None | 89 | 307,952 | 5.7 (4.3, 7.4) |
Public | 844 | 3,371,338 | 62.0 (58.0, 65.8) |
Private | 374 | 1,761,024 | 32.4 (28.5, 36.5) |
Physical activity | |||
Inactive | 98 | 469,079 | 8.6 (6.9, 10.6) |
Active | 38 | 162,524 | 3.0 (2.0, 4.5) |
Very Active | 1171 | 4,808,711 | 88.4 (86.0, 90.5) |
BMI category 2 | |||
Normal | 284 | 1,419,482 | 26.3 (22.9, 30.0) |
Overweight | 515 | 2,092,387 | 38.7 (35.6, 42.0) |
Obesity | 499 | 1,890,403 | 35.0 (32.2, 37.9) |
Abdominal obesity | 1000 | 3,781,384 | 72.0 (68.8, 75.0) |
Dyslipidemias | |||
Total cholesterol (≥200 mg/dL) | 523 | 1,935,626 | 35.6 (32.2, 39.2) |
LDL cholesterol (≥100 mg/dL) | 903 | 5,435,430 | 65.2 (62.4, 67.9) |
HDL cholesterol (<40 mg/dL) | 549 | 2,410,851 | 44.3 (40.5, 48.2) |
VLDL cholesterol (>30 mg/dL) | 754 | 3,031,427 | 55.8 (52.4, 59.1) |
Non-HDL cholesterol (>130 mg/dL) | 875 | 5,435,430 | 62.5 (59.3, 65.7) |
Triglycerides (>150 mg/dL)c | 756 | 3,034,931 | 55.8 (52.4, 59.2) |
Hypertension | 252 | 686,869 | 15.5 (13.3, 18.1) |
Prediabetes 1 | Diabetes 2 | |||
---|---|---|---|---|
% (95% CI) | OR (95% CI)3 | % (95% CI) | OR (95% CI) 3 | |
Overall | 26.4 (23.1, 29.9) | -- | 13.6 (11.7, 15.7) | -- |
Gender | ||||
Men | 25.3 (19.5, 32.1) | Ref | 13.1 (10.1, 17.0) | Ref |
Women | 27.3 (23.0, 32.0) | 1.1 (0.7, 1.7) | 13.9 (11.9, 16.2) | 1.0 (0.7, 1.5) |
Age group | ||||
20–39 | 20.6 (16.5, 25.5) | Ref | 4.3 (3.0, 6.1) | Ref |
40–59 | 32.5 (28.2, 37.1) | 2.3 (1.7, 3.1) | 20.4 (17.3, 23.9) | 4.9 (3.2, 7.4) |
60+ | 34.2 (27.4, 41.7) | 3.8 (2.3, 6.5) | 38.2 (29.9, 47.3) | 10.2 (6.1, 17.2) |
Education | ||||
Elementary or less | 33.3 (27.8, 39.4) | Ref | 26.3 (21.3, 31.9) | Ref |
Secondary | 26.1 (20.4, 32.8) | 0.8 (0.5, 1.2) | 17.4 (13.0, 22.8) | 1.0 (0.6, 1.6) |
High school or higher | 24.0 (19.6, 29.0) | 0.7 (0.5, 1.0) | 7.0 (5.2, 9.5) | 0.5 (0.3, 0.8) |
Socioeconomic status | ||||
Low | 29.0 (24.4, 34.1) | Ref | 20.8 (16.7, 25.6) | Ref |
Middle | 27.8 (22.8, 33.5) | 0.9 (0.6, 1.4) | 13.6 (11.1, 16.5) | 0.7 (0.5, 1.1) |
High | 23.7 (18.9, 29.3) | 0.7 (0.5, 1.2) | 9.7 (7.1, 13.2) | 0.6 (0.4, 1.1) |
Primary health care provider | ||||
None | 18.5 (8.9, 34.7) | Ref | 34.1 (22.5, 47.9) | Ref |
Public | 27.3 (23.1, 31.9) | 1.1 (0.5, 2.7) | 13.7(11.3, 16.6) | 0.3 (0.1, 0.6) |
Private | 25.9 (20.4, 32.3) | 1.1 (0.4, 2.9) | 9.6 (6.9, 13.2) | 0.2 (0.1, 0.5) |
Unaware | Aware | OR for Diabetes Awareness (95% CI) 1 | |
---|---|---|---|
% (95% CI) | % (95% CI) | ||
Overall | 29.5 (24.3, 35.2) | 70.5 (64.8, 75.7) | |
Gender | |||
Men | 33.2 (25.0, 42.6) | 66.8 (57.4, 75.0) | Ref |
Women | 25.1 (18.2, 33.6) | 74.9 (66.4, 81.8) | 1.4 (0.7, 2.9) |
Age group | |||
20–39 | 45.8 (26.1, 66.8) | 54.2 (33.2, 73.9) | Ref |
40–59 | 29.9 (22.0, 39.2) | 70.1 (60.8, 78.0) | 2.2 (0.8, 6.4) |
60+ | 18.2 (8.1, 35.8) | 81.8 (64.2, 91.8) | 3.6 (0.7, 18.1) |
Education | |||
Elementary or less | 24.4 (14.7, 37.7) | 75.6 (62.2, 85.2) | Ref |
Secondary | 38.4 (25.4, 53.1) | 61.6 (46.9, 74.6) | 0.7 (0.2, 2.0) |
High school or higher | 24.7 (14.1, 40.0) | 75.3 (60.4, 85.8) | 1.2 (0.4, 3.9) |
Socioeconomic status | |||
Low | 30.1 (21.6, 40.1) | 69.9 (59.9, 78.4) | Ref |
Middle | 27.6 (19.1, 38.0) | 72.4 (62.0, 80.9) | 1.1 (0.5, 2.4) |
High | 31.1 (20.1, 44.7) | 68.9 (55.3, 79.8) | 0.9 (0.4, 2.0) |
Primary health care provider | |||
None | 14.4 (5.3, 33.9) | 85.6 (66.1, 94.7) | Ref |
Public | 27.0 (18.5, 37.7) | 73.0 (62.3, 81.5) | 0.3 (0.1, 1.2) |
Private | 45.5 (32.2, 59.4) | 54.5 (40.6, 67.8) | 0.2 (0.1, 0.6) |
Diabetes Quality of Care Indicators | Total (n = 297) | HbA1C < 7.0% (n = 81) | HbA1C > 7.0% (n = 216) | p Value 1 |
---|---|---|---|---|
Quality health care indicators | ||||
Medical consultations (4–12 per year) | 62.7 (55.2, 69.6) | 52.8 (40.7, 64.6) | 66.8 (57.9, 74.6) | 0.056 |
HbA1C measurements (at least 2 per year) | 5.5 (3.0, 9.7) | 4.9 (1.8, 12.9) | 7.6 (3.4, 16.2) | 0.476 |
Glucose measurements (4–12 per year) | 56.5 (48.2, 64.5) | 58.5 (44.4, 71.3) | 56.8 (47.5, 65.7) | 0.841 |
Early detection of cardiovascular risk factors 2 | ||||
Total cholesterol and triglycerides measurements | 4.7 (2.3, 9.4) | 6.0 (2.0, 17.1) | 4.0 (1.7, 9.3) | 0.543 |
Blood pressure measurements | 3.6 (2.2, 5.8) | 5.4 (1.9, 14.5) | 4.1 (1.4, 11.6) | 0.783 |
Screening for complications 2 | ||||
Measurement of protein levels in urine | 26.6 (19.5, 35.2) | 20.6 (9.4, 39.4) | 29.1 (20.5, 39.5) | 0.371 |
Ophthalmological evaluation | 16.5 (11.6, 23.1) | 20.6 (12.1, 33.0) | 14.8 (9.3, 22.7) | 0.329 |
Feet examination | 53.0 (44.7, 61.0) | 38.1 (26.0, 51.8) | 59.1 (49.6, 67.9) | 0.010 |
Lifestyle recommendations by a physician | ||||
Diet | 71.3 (63.8, 77.7) | 66.4 (52.4, 78.0) | 73.3 (64.9, 80.3) | 0.333 |
Physical activity | 57.9 (51.9, 63.6) | 45.7 (33.4, 58.6) | 62.9 (55.5, 69.7) | 0.033 |
Both | 75.2 (69.1, 80.5) | 69.8 (57.4, 79.8) | 77.5 (70.6, 83.1) | 0.214 |
Pharmacological treatment | ||||
Diabetes treatment | 86.0 (79.2, 90.9) | 78.4 (65.3, 87.5) | 89.2 (81.1, 94.1) | 0.072 |
Insulin | 9.5 (6.0, 14.9) | 5.7 (2.3, 13.0) | 11.1 (6.6, 18.2) | 0.161 |
Pills | 64.6 (57.0, 71.6) | 70.1 (59.3, 79.1) | 62.4 (52.8, 71.1) | 0.246 |
Both (insulin and pills) | 11.9 (8.0, 17.5) | 2.6 (0.9, 7.6) | 15.7 (10.3, 23.4) | 0.001 |
High blood pressure treatment | 78.9 (64.9, 88.3) | 80.8 (49.8, 94.7) | 78.2 (64.1, 87.8) | 0.825 |
High cholesterol treatment | 67.9 (51.0,81.1) | 98.3 (86.9, 99.8) | 56.7 (39.1, 72.8) | <0.001 |
% (95% CI) 1 | |
---|---|
Treatment targets | |
LDL cholesterol < 100 mg/dLd | 28.3 (22.4, 35.0) |
Blood pressure < 130/80 mmHg | 44.9 (37.6, 52.5) |
HbA1c < 7% | 29.0 (22.2, 37.0 |
Meeting three targets | 4.1 (1.7, 9.5) |
Treatment outcomes 2 | |
Diabetic coma | 98.6 (96.4, 99.5) |
Cardiovascular disease | 89.3 (83.5, 93.2) |
Nephropathy | 90.0 (83.0, 94.3) |
Neuropathy | 60.6 (52.2, 68.4) |
Retinopathy | 51.9 (45.0, 58.8) |
No complications | 35.4 (29.0, 42.0) |
HbA1c < 7% | LDL Cholesterol a < 100 mg/dL | Blood Pressure < 130/80 mmHg | ||||
---|---|---|---|---|---|---|
% (95% CI) | OR (95% CI) | % (95% CI) | OR (95% CI) | % (95% CI) | OR (95% CI) | |
Gender | ||||||
Men | 20.3 (12.7, 30.8) | Ref | 39.0 (29.2, 50.0) | Ref | 46.6 (41.1, 63.5) | Ref |
Women | 35.9 (26.0, 47.1) | 2.8 (1.3, 6.1) | 20.1 (13.3, 29.2) | 0.4 (0.2, 0.9) | 43.3 (34.8, 51.4) | 1.0 (0.5, 1.9) |
Age group | ||||||
20–39 | 62.3 (39.9, 80.4) | Ref | 26.9 (11.0, 52.5) | Ref | 77.6 (55.2, 90.7) | Ref |
40–59 | 23.4 (16.2, 32.6) | 0.1 (0.0, 0.3) | 30.4 (22.8, 39.2) | 1.2 (0.3, 4.3) | 40.7 (32.2, 49.8) | 0.2 (0.1, 0.7) |
60+ | 25.6 (16.8, 37.0) | 0.1 (0.0, 0.5) | 25.0 (15.4, 38.0) | 1.1 (0.3, 4.3) | 38.0 (27.2, 50.1) | 0.2 (0.1, 0.6) |
Education | ||||||
Elementary or less | 26.2 (16.0, 38.5) | Ref | 18.8 (12.1, 28.0) | Ref | 38.4 (28.2, 49.7) | Ref |
Secondary | 33.8 (23.4, 46.10) | 1.1 (0.4, 2.9) | 26.7 (17.7, 38.2) | 1.4 (0.6, 3.4) | 52.5 (40.6, 64.2) | 1.2 (0.6, 2.6) |
High school or higher | 28.3 (17.0, 43.2) | 1.2 (0.5, 3.0) | 42.5 (29.0, 57.2) | 3.1 (0.9, 9.8) | 44.9 (29.9, 60.9) | 1.1 (0.4, 2.8) |
Socioeconomic status | ||||||
Low | 24.6 (13.4, 40.8) | Ref | 31.3 (22.5, 41.7) | Ref | 45.6 (35.6, 56.1) | Ref |
Middle | 26.3 (16.7, 38.9) | 1.2 (0.4, 3.4) | 22.4 (13.6, 34.7) | 0.4 (0.2, 0.9) | 45.4 (32.3, 59.2) | 1.0 (0.4, 2.4) |
High | 38.1 (24.6, 54.7) | 2.6 (0.9, 7.6) | 32.3 (20.4, 47.0) | 0.7 (0.2, 2.0) | 42.7 (29.3, 57.2) | 1.0 (0.4, 2.2) |
Primary health care providera | ||||||
None | 24.8 (13.8, 40.7) | Ref | 23.5 (11.9, 41.1) | Ref | 57.7 (37.6, 75.5) | Ref |
Public | 31.8 (23.8, 41.0) | 1.8 (0.7, 5.0) | 29.2 (20.3, 40.0) | 1.9 (0.5, 6.9) | 44.3 (33.8, 55.3) | 0.7 (0.2, 2.0) |
Private | 23.9 (12.8, 40.3) | 1.0 (0.3, 3.6) | 29.5 (7.2, 45.96) | 1.7 (0.4, 6.8) | 33.7 (20.2, 50.5) | 0.4 (0.1, 1.2) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barquera, S.; Hernández-Alcaraz, C.; Jáuregui, A.; Medina, C.; Mendoza-Herrera, K.; Pedroza-Tobias, A.; Tolentino Mayo, L.; Guillen Pineda, L.E.; López-Ridaura, R.; Aguilar Salinas, C.A. Diabetes Awareness, Treatment, and Control among Mexico City Residents. Diabetology 2021, 2, 16-30. https://doi.org/10.3390/diabetology2010002
Barquera S, Hernández-Alcaraz C, Jáuregui A, Medina C, Mendoza-Herrera K, Pedroza-Tobias A, Tolentino Mayo L, Guillen Pineda LE, López-Ridaura R, Aguilar Salinas CA. Diabetes Awareness, Treatment, and Control among Mexico City Residents. Diabetology. 2021; 2(1):16-30. https://doi.org/10.3390/diabetology2010002
Chicago/Turabian StyleBarquera, Simón, César Hernández-Alcaraz, Alejandra Jáuregui, Catalina Medina, Kenny Mendoza-Herrera, Andrea Pedroza-Tobias, Lizbeth Tolentino Mayo, Luz Elizabeth Guillen Pineda, Ruy López-Ridaura, and Carlos A. Aguilar Salinas. 2021. "Diabetes Awareness, Treatment, and Control among Mexico City Residents" Diabetology 2, no. 1: 16-30. https://doi.org/10.3390/diabetology2010002
APA StyleBarquera, S., Hernández-Alcaraz, C., Jáuregui, A., Medina, C., Mendoza-Herrera, K., Pedroza-Tobias, A., Tolentino Mayo, L., Guillen Pineda, L. E., López-Ridaura, R., & Aguilar Salinas, C. A. (2021). Diabetes Awareness, Treatment, and Control among Mexico City Residents. Diabetology, 2(1), 16-30. https://doi.org/10.3390/diabetology2010002